GlaxoSmithKline Pharmaceuticals Ltd
NSE:GLAXO
Gross Margin
GlaxoSmithKline Pharmaceuticals Ltd
Gross Margin is the amount of money a company retains after incurring the direct costs associated with producing the goods it sells and the services it provides. The higher the gross margin, the more capital a company retains, which it can then use to pay other costs or satisfy debt obligations.
Gross Margin Across Competitors
| Country | Company | Market Cap |
Gross Margin |
||
|---|---|---|---|---|---|
| IN |
|
GlaxoSmithKline Pharmaceuticals Ltd
NSE:GLAXO
|
487.9B INR |
62%
|
|
| US |
|
Eli Lilly and Co
NYSE:LLY
|
779.4B USD |
81%
|
|
| UK |
|
Dechra Pharmaceuticals PLC
LSE:DPH
|
440.4B GBP |
56%
|
|
| US |
|
Johnson & Johnson
NYSE:JNJ
|
394B USD |
69%
|
|
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
2.1T DKK |
85%
|
|
| CH |
|
Roche Holding AG
SIX:ROG
|
236.5B CHF |
73%
|
|
| UK |
|
AstraZeneca PLC
LSE:AZN
|
177B GBP |
82%
|
|
| US |
|
Merck & Co Inc
NYSE:MRK
|
225.9B USD |
81%
|
|
| CH |
|
Novartis AG
SIX:NOVN
|
199.7B CHF |
75%
|
|
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
167.6B USD |
68%
|
|
| US |
|
Pfizer Inc
NYSE:PFE
|
142.8B USD |
74%
|
GlaxoSmithKline Pharmaceuticals Ltd
Glance View
GlaxoSmithKline Pharmaceuticals Ltd., a subsidiary of the global healthcare juggernaut GSK, stands as a pillar in the pharmaceutical industry, with roots deeply entrenched in innovation and a robust pipeline of healthcare products. This company weaves a narrative of relentless pursuit in the creation and distribution of a wide variety of medicines and vaccines, aimed at improving the quality of human life. Operating predominantly in the areas of pharmaceuticals, vaccines, and consumer healthcare, GSK integrates cutting-edge research with strategic collaborations. This enables them to address pressing medical needs, such as respiratory diseases, HIV, infectious diseases, and oncology, amongst others, thereby leveraging their expertise to cater to diverse healthcare demands. The heart of their revenue generation lies in the seamless amalgamation of research acumen and market presence. By investing significantly in research and development, GSK continually introduces groundbreaking therapies and health solutions. The company has adeptly structured its operations to create a strong global presence, which not only involves selling directly to healthcare providers and governments but also innovating its supply chain to maximize reach. Moreover, GSK's astute marketing efforts ensure that their products are not just effective but also attuned to consumer needs. With a focus on sustainable growth and transformative medicines, GSK’s story becomes a testament to how science-driven strategies can forge pathways to a healthier world while simultaneously fueling the company’s economic engine.
See Also
Gross Margin is the amount of money a company retains after incurring the direct costs associated with producing the goods it sells and the services it provides. The higher the gross margin, the more capital a company retains, which it can then use to pay other costs or satisfy debt obligations.
Based on GlaxoSmithKline Pharmaceuticals Ltd's most recent financial statements, the company has Gross Margin of 62.1%.
You don't have any saved screeners yet